Book-to-Bill 1.4 With Capex Guided Below Last Year's Level
They raised guidance to the upper half of the range and warned that the order intake driving it may not continue in the same breath.
Thesis: Jenoptik is a lithography and inspection optics supplier two steps removed from hyperscaler capex, selling into WFE OEMs. The semi segment is genuinely firing: 32% EBITDA margin, cost program embedded, mix shifting, EUR 170-180M quarterly semi orders. But CapEx is guided below last year against a 1.4 book-to-bill, so the bottleneck is their own clean room and headcount, not demand. Management itself flagged that some semi orders are placed to secure capacity and that H1 orders arrived early. Revenue converts from backlog this year, so the earnings print holds. The order cycle is the part they have already pre-announced will decelerate.
Verdict: HOLD — Conviction: MEDIUM
Catalyst: Q3 order intake against the EUR 170-180M semi run rate. The strategy review with outcomes 'at the end of this year at the earliest' is a secondary, unquantified option.
Key Risk: Capacity-securing semi orders unwind as lead times normalize while CapEx below last year leaves no ability to backfill, plus German collective agreement and new FTEs landing as factor-cost lag against a decelerating order book.
The Tell: In the same answer where the CFO confirmed semi run-rate orders of EUR 170-180M, she volunteered: 'in a Semi ramp-up, of course, it could also be that some customers are putting in orders that are maybe mainly there to secure capacity.' She flagged backlog quality herself while raising guidance on that backlog.
Detected Patterns
Beat and Raise Machine: Order intake +50% YoY, book-to-bill 1.4, backlog EUR 825M, EBITDA +25% with 400bps expansion, EPS 0.69 vs 0.42, and guidance moved to the upper half of both revenue (5-9%) and EBITDA margin (19-21%). CFO says semi can land 'a tad above the 30% range'.
Margin Expansion Engine: Gross margin up on the executed cost reduction program plus semi mix, with CapEx guided slightly below last year. Output per euro of investment is rising. Semi at ~32% EBITDA pulls group mix even with two units shrinking.
Backlog Quality: CFO volunteered that orders came 'surprisingly early', may not continue in the next two quarters, and that 'some customers are putting in orders that are maybe mainly there to secure capacity'. Biophotonics +45% carries admitted geopolitical pull-forward and one undisclosed multi-year MedTech order while segment revenue fell ~5%.
Capacity Ceiling: Book-to-bill 1.4 against CapEx slightly below last year. Only named expansion is the Jena clean room for semi-inspection. Asked directly about headcount and supplier capacity into 2027, CFO answered 'for now... not tangibly constrained' qualified by 'there may be certain risks'.
Zero Pricing Power Despite Constraints: Asked point-blank whether it raised prices to offset input costs while running at 50% order growth, the CFO declined: 'I am afraid I will be a little, let us say, vague in the color I can give.' Factor costs are rising via the German collective agreement and new FTEs.
AI Label Without Substance: Microlens arrays for optical datacom growing 'on a significantly smaller base', CFO refuses to size it pending a strategy review from a new executive team with outcomes 'at the end of this year at the earliest'. AR/VR: 'no major order intake in the very near future'.
Friction Level: MODERATE_FRICTION — Both sides accept the print is real. Disagreement is over backlog quality: EUR 825M covers into 2027 and converts 60-65% this year, or it is padded with capacity-securing and geopolitical pull-forward orders that unwind in H2.
Report not found
The report data is no longer available. Please return to the archive.
Book-to-Bill 1.4 With Capex Guided Below Last Year's Level | Silicon Signal